{
    "clinical_study": {
        "@rank": "144796", 
        "arm_group": [
            {
                "arm_group_label": "Pembrolizumab + PegIFN-2b", 
                "arm_group_type": "Experimental", 
                "description": "pembrolizumab intravenously (IV) at assigned dose every 2 or 3 weeks + PegIFN-2b subcutaneously (SC) at assigned dose once a week in each 6-week cycle."
            }, 
            {
                "arm_group_label": "Pembrolizumab + IPI", 
                "arm_group_type": "Experimental", 
                "description": "pembrolizumab IV at assigned dose every 2 or 3 weeks + IPI IV at assigned dose every 3 weeks for a total of two 6-week cycles."
            }, 
            {
                "arm_group_label": "Pembrolizumab (Part 2 only)", 
                "arm_group_type": "Experimental", 
                "description": "pembrolizumab IV monotherapy at assigned dose and schedule."
            }
        ], 
        "brief_summary": {
            "textblock": "This study is being done to analyze the safety, tolerability, and efficacy of treatment for\n      advanced melanoma (MEL) and renal cell carcinoma (RCC) using combination regimens of\n      pembrolizumab (MK-3475) + pegylated interferon alfa-2b (PegIFN-2b) and pembrolizumab +\n      ipilimumab (IPI). The primary hypothesis is that these combinations will be sufficiently\n      well-tolerated to permit continued clinical investigation."
        }, 
        "brief_title": "Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029)", 
        "completion_date": {
            "#text": "January 2018", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Renal Cell Carcinoma", 
            "Melanoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Renal Cell", 
                "Melanoma"
            ]
        }, 
        "detailed_description": {
            "textblock": "The trial is being done in two parts: Part 1 is dose-finding part to define the maximum\n      tolerated dose (MTD) for the drug combinations. In Part 1, different dose levels and\n      schedules will be used to find the recommended Phase 2 dose (RP2D) for each combination.\n      Part 2 is a randomized portion of the trial and will evaluate preliminary efficacy of the\n      drug combinations given in 6-week cycles for advanced MEL participants. Doses used in Part 2\n      will be decided by assessment of dose escalation cohorts in this study and external\n      information."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically- or cytologically-confirmed diagnosis of advanced/unresectable or\n             metastatic MEL or RCC (Part 1 only) with predominantly clear cell elements\n\n          -  MEL subjects may be treatment na\u00efve or may have received prior lines of therapy for\n             metastatic disease\n\n          -  RCC subjects must have received >=1 prior line of therapy for metastatic disease\n\n          -  Measurable disease as defined by RECIST 1.1\n\n          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1\n\n          -  Adequate organ function\n\n          -  Resolution of toxic effect(s) of the most recent prior chemotherapy to Grade 1 and/or\n             recovered from major surgery or radiation therapy\n\n          -  Female participants of childbearing potential must be willing to use adequate\n             contraception during the course of the study through 120 days after the last dose of\n             study drug\n\n          -  Male participants must agree to use an adequate method of contraception starting with\n             the first dose of study therapy through 120 days after the last dose of study drug\n\n        Exclusion Criteria\n\n          -  Uveal or ocular MEL\n\n          -  Diagnosis of immunodeficiency or receiving systemic steroid therapy or any other form\n             of immunosuppressive therapy within 7 days prior to the first dose of study drug\n\n          -  Prior therapy with an anti-programmed cell death (PD)-1, anti-PD-L1, anti-PD-L2,\n             anti-CD137 antibody, anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) or\n             other immune checkpoint inhibitor agents\n\n          -  Monoclonal antibody for direct antineoplastic treatment, prior chemotherapy, targeted\n             small molecule therapy, or radiation therapy within 4 weeks prior to study Day 1 or\n             has not recovered from adverse events due to agents administered more than 4 weeks\n             earlier\n\n          -  Known additional malignancy that is progressing or requires active treatment with the\n             exception of basal cell carcinoma of the skin, squamous cell carcinoma of the skin,\n             or in situ cervical cancer that has undergone potentially curative therapy\n\n          -  Known active central nervous system (CNS) metastases and/or carcinomatous meningitis\n\n          -  Active autoimmune disease requiring systemic treatment within the past 3 months or a\n             documented history of clinically severe autoimmune disease, or a syndrome that\n             requires systemic steroids or immunosuppressive agents\n\n          -  Active, non-infectious pneumonitis\n\n          -  Active infection requiring systemic therapy\n\n          -  Pregnant or breastfeeding, or expecting to conceive or father children within the\n             projected duration of the trial from screening through 120 days after the last dose\n             of study drug\n\n          -  Prior therapy with interferon alfa for treatment of metastatic disease\n\n          -  Uncontrolled thyroid dysfunction\n\n          -  Uncontrolled diabetes mellitus.\n\n          -  Known history of human immunodeficiency virus (HIV)\n\n          -  Known active Hepatitis B or Hepatitis C\n\n          -  Received a live vaccine within 30 days prior to first dose of study drug"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "195", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 14, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02089685", 
            "org_study_id": "3475-029", 
            "secondary_id": "2013-004072-36"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Pembrolizumab + PegIFN-2b", 
                    "Pembrolizumab + IPI", 
                    "Pembrolizumab (Part 2 only)"
                ], 
                "intervention_name": "Pembrolizumab", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Pembrolizumab + PegIFN-2b", 
                "intervention_name": "PegIFN-2b", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Pembrolizumab + IPI", 
                "intervention_name": "Ipilimumab", 
                "intervention_type": "Biological"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Interferon-alpha", 
                "Interferon Alfa-2a", 
                "Interferon Alfa-2b", 
                "Interferons", 
                "Peginterferon alfa-2b", 
                "Reaferon"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "June 3, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90095"
                    }, 
                    "name": "Call for Information (Investigational Site 0001)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Washington", 
                        "country": "United States", 
                        "state": "District of Columbia", 
                        "zip": "20016"
                    }, 
                    "name": "Call for Information (Investigational Site 0003)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98109"
                    }, 
                    "name": "Call for Information (Investigational Site 0006)"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase I/II Clinical Trial to Study the Safety and Tolerability of MK-3475 + Pegylated Interferon Alfa-2b (PEG-IFN) and MK-3475 + Ipilimumab (IPI) in Subjects With Advanced Melanoma (MEL) and Renal Cell Carcinoma (RCC)", 
        "overall_contact": {
            "last_name": "Toll Free Number", 
            "phone": "1-888-577-8839"
        }, 
        "overall_official": {
            "affiliation": "Merck Sharp & Dohme Corp.", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "April 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Number of participants with dose-limiting toxicities (Part 1)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 6 weeks (Cycle 1)"
            }, 
            {
                "measure": "Number of participants experiencing adverse events (AEs)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "measure": "Number of participants discontinuing study drug because of AEs", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "measure": "Progression-free survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02089685"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Overall Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 response", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "measure": "Objective response rate (ORR)", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "measure": "Duration of Response (DoR)", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "measure": "Overall Survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }
        ], 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}